Uveitis correction sharpens the provenance of the single-cell dataset
A published correction has tightened the Methods section of a single-cell study on non-infectious uveitis and viral uveitis, adding a clarification that part of the work included re-analysis of non-infectious uveitis samples previously published elsewhere. The revision does not alter the biological premise of the paper, but it matters because single-cell immunology depends on exact sample provenance, especially when investigators are comparing inflammatory programs across ocular disease states.
In a field where small changes in collection, processing, and cohort definition can reshape downstream clustering and pathway interpretation, the correction makes the study’s structure more explicit. It places the re-used material in context and aligns the methods with the data lineage expected in high-resolution immune profiling.
Non-infectious uveitis cohort details now read with greater precision
The corrected Methods text states that 21 human participants with non-infectious uveitis were enrolled under Declaration of Helsinki principles and with institutional review board approval at Washington University in St. Louis. Written informed consent was obtained before inclusion. For ocular sampling, the cohort consisted of participants with active anterior uveitis, defined as at least 1+ anterior chamber cell, corresponding to more than 6 cells per high-powered field, and paired ocular and blood samples were collected.
A one-cell difference in description can matter in single-cell work, where the starting material is sparse and the cellular makeup of the aqueous humor can be extremely sensitive to disease activity. Here, the explicit definition of active anterior uveitis anchors the inflammatory threshold used to obtain ocular fluid and helps frame the immune populations downstream of the collection pipeline.
Sample handling shaped the cellular readout before sequencing began
The revised methods provide a more complete account of how the ocular and blood specimens were processed. Approximately 100–200 μL of anterior chamber fluid was removed and centrifuged at 400 g for 5 minutes, after which the aqueous fluid was removed. Blood was drawn by venipuncture into EDTA tubes and purified by Ficoll–Hypaque density gradient centrifugation. The anterior chamber cells and peripheral blood mononuclear cells were then cryopreserved in fetal bovine serum with 10% dimethyl sulfoxide and stored at –140 °C.
Those pre-analytic steps are not clerical footnotes; they help determine which leukocyte subsets survive handling and which transcriptional states remain intact for single-cell sequencing. Ocular inflammation research is especially vulnerable to artifacts from low cell numbers, temperature shifts, and delayed processing. A small deviation in handling can alter cell viability, distort rare populations, and complicate the biological comparison between inflamed eye tissue and blood-derived immune cells.
The added detail therefore strengthens interpretability. It tells readers how the study minimized cellular loss during an inherently fragile workflow and how the authors handled paired ocular-blood sampling in a disease setting where the eye often yields only a narrow window into active immune biology.
Re-analysis is not a flaw, but it must be declared clearly
The clarification that the work includes re-analysis of previously published non-infectious uveitis samples is central to how the paper should be read. Re-analysis can be scientifically valuable when investigators apply a new analytic lens, compare disease states using a shared platform, or mine archived material for features that were not accessible in the original publication. In ocular immunology, where biopsy material is limited and sampling often cannot be repeated, re-use of high-quality specimens is often necessary to build a coherent dataset.
Even so, transparency about re-analysis protects the integrity of the scientific record. Readers need to know whether the dataset is entirely de novo or built partly from earlier material, because that affects how they interpret novelty, cohort composition, and the scope of the conclusions. The correction does exactly that: it clarifies the experimental lineage without altering the underlying methods or the reported design of the study.
Why the correction matters for ocular immunology
Single-cell sequencing in uveitis sits at the intersection of immunology and ophthalmology, where the biological signal may come from only a handful of cells collected directly from the anterior chamber. In that setting, method clarity is essential for any comparison among B cells, T cells, and other immune populations that might differ between non-infectious and viral disease. The corrected text does not introduce a new hypothesis, a new cohort size, or a different clinical endpoint. Instead, it makes the lineage of the dataset legible, which is often the difference between a reproducible analysis and an ambiguous one.
The correction also reinforces a practical truth about translational eye research: the value of a dataset depends not only on sequencing depth, but on the chain of custody that begins the moment fluid leaves the anterior chamber. When that chain is explicit, downstream interpretation becomes more reliable, especially in studies aiming to define distinct mechanisms in ocular inflammation.
In this case, the substantive scientific message remains tied to the original single-cell comparison, while the correction keeps the methodological record aligned with how the samples were actually assembled and re-used. Future readers can now judge the analysis with a clearer understanding of what was newly collected, what was previously published, and how the ocular and blood specimens moved through the experimental pipeline.